FI3800257T3 - Pan-genotyyppisiä aineita influenssavirusta vastaan ja menetelmiä niiden käyttämiseksi - Google Patents
Pan-genotyyppisiä aineita influenssavirusta vastaan ja menetelmiä niiden käyttämiseksi Download PDFInfo
- Publication number
- FI3800257T3 FI3800257T3 FIEP20208373.9T FI20208373T FI3800257T3 FI 3800257 T3 FI3800257 T3 FI 3800257T3 FI 20208373 T FI20208373 T FI 20208373T FI 3800257 T3 FI3800257 T3 FI 3800257T3
- Authority
- FI
- Finland
- Prior art keywords
- oligonucleotide
- compound
- nucleotides
- ina
- letters indicate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- 241000712461 unidentified influenza virus Species 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 101000702394 Homo sapiens Signal peptide peptidase-like 2A Proteins 0.000 claims 4
- 206010022000 influenza Diseases 0.000 claims 4
- 108020000999 Viral RNA Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 241000712431 Influenza A virus Species 0.000 claims 2
- 108091034135 Vault RNA Proteins 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302548P | 2016-03-02 | 2016-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3800257T3 true FI3800257T3 (fi) | 2024-06-19 |
Family
ID=59743201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20208373.9T FI3800257T3 (fi) | 2016-03-02 | 2017-03-01 | Pan-genotyyppisiä aineita influenssavirusta vastaan ja menetelmiä niiden käyttämiseksi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10597658B2 (https=) |
| EP (3) | EP3800257B1 (https=) |
| JP (3) | JP7536272B2 (https=) |
| CN (1) | CN108778344A (https=) |
| CA (1) | CA3014776A1 (https=) |
| DK (1) | DK3800257T3 (https=) |
| ES (1) | ES2981765T3 (https=) |
| FI (1) | FI3800257T3 (https=) |
| HR (1) | HRP20240765T1 (https=) |
| HU (1) | HUE066977T2 (https=) |
| LT (1) | LT3800257T (https=) |
| PL (1) | PL3800257T3 (https=) |
| PT (1) | PT3800257T (https=) |
| RS (1) | RS65707B1 (https=) |
| SI (1) | SI3800257T1 (https=) |
| SM (1) | SMT202400253T1 (https=) |
| WO (1) | WO2017151795A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021201996A1 (en) * | 2020-02-14 | 2021-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against respiratory viruses and methods of using the same |
| US12522827B2 (en) | 2016-03-02 | 2026-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
| US11339392B2 (en) | 2016-03-02 | 2022-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT69956A (en) * | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| US20040242518A1 (en) | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| AU2006235364A1 (en) * | 2005-04-08 | 2006-10-19 | Marina Biotech, Inc. | RNAi therapeutic for respiratory virus infection |
| EP1937066A4 (en) * | 2005-08-18 | 2008-12-24 | Alnylam Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES |
| WO2007084359A2 (en) * | 2006-01-17 | 2007-07-26 | Oligos Etc., Inc. | Compositions and methods for the treatment of influenza infection |
| CN100562342C (zh) * | 2006-01-17 | 2009-11-25 | 奥林格斯技术有限公司 | 防治流感病毒感染的寡核苷酸药物 |
| CA2666657A1 (en) * | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| US20090042823A1 (en) | 2007-08-10 | 2009-02-12 | Mdrna, Inc. | Uses of broad spectrum rnai therapeutics against influenza |
| CA2729757A1 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| AU2009310557B2 (en) * | 2008-10-27 | 2014-09-11 | Academisch Ziekenhuis Leiden | Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA |
| EP2499248B1 (en) | 2009-11-13 | 2017-01-04 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| EP2519633B1 (en) * | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| CA2800281C (en) * | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
-
2017
- 2017-03-01 EP EP20208373.9A patent/EP3800257B1/en active Active
- 2017-03-01 RS RS20240693A patent/RS65707B1/sr unknown
- 2017-03-01 FI FIEP20208373.9T patent/FI3800257T3/fi active
- 2017-03-01 EP EP24159464.7A patent/EP4389221A3/en active Pending
- 2017-03-01 CN CN201780014078.0A patent/CN108778344A/zh active Pending
- 2017-03-01 CA CA3014776A patent/CA3014776A1/en active Pending
- 2017-03-01 US US16/081,818 patent/US10597658B2/en active Active
- 2017-03-01 SI SI201731528T patent/SI3800257T1/sl unknown
- 2017-03-01 SM SM20240253T patent/SMT202400253T1/it unknown
- 2017-03-01 HU HUE20208373A patent/HUE066977T2/hu unknown
- 2017-03-01 EP EP17760733.0A patent/EP3423107A4/en not_active Withdrawn
- 2017-03-01 ES ES20208373T patent/ES2981765T3/es active Active
- 2017-03-01 PT PT202083739T patent/PT3800257T/pt unknown
- 2017-03-01 LT LTEP20208373.9T patent/LT3800257T/lt unknown
- 2017-03-01 DK DK20208373.9T patent/DK3800257T3/da active
- 2017-03-01 JP JP2018543209A patent/JP7536272B2/ja active Active
- 2017-03-01 WO PCT/US2017/020241 patent/WO2017151795A1/en not_active Ceased
- 2017-03-01 PL PL20208373.9T patent/PL3800257T3/pl unknown
- 2017-03-01 HR HRP20240765TT patent/HRP20240765T1/hr unknown
-
2022
- 2022-10-07 JP JP2022162516A patent/JP2022176378A/ja not_active Withdrawn
-
2025
- 2025-04-02 JP JP2025061328A patent/JP2025096365A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3800257T3 (pl) | 2024-09-16 |
| DK3800257T3 (da) | 2024-06-24 |
| HRP20240765T1 (hr) | 2024-09-13 |
| EP3423107A4 (en) | 2020-01-15 |
| JP2025096365A (ja) | 2025-06-26 |
| SMT202400253T1 (it) | 2024-09-16 |
| RS65707B1 (sr) | 2024-08-30 |
| US10597658B2 (en) | 2020-03-24 |
| JP2022176378A (ja) | 2022-11-25 |
| WO2017151795A1 (en) | 2017-09-08 |
| EP3800257A1 (en) | 2021-04-07 |
| EP4389221A3 (en) | 2024-11-20 |
| LT3800257T (lt) | 2024-07-25 |
| HUE066977T2 (hu) | 2024-09-28 |
| JP2019511471A (ja) | 2019-04-25 |
| EP4389221A2 (en) | 2024-06-26 |
| CA3014776A1 (en) | 2017-09-08 |
| JP7536272B2 (ja) | 2024-08-20 |
| US20190136242A1 (en) | 2019-05-09 |
| ES2981765T3 (es) | 2024-10-10 |
| EP3423107A1 (en) | 2019-01-09 |
| PT3800257T (pt) | 2024-06-26 |
| EP3800257B1 (en) | 2024-05-01 |
| SI3800257T1 (sl) | 2025-04-30 |
| CN108778344A (zh) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102540359B1 (ko) | B형 간염 바이러스 감염에 대한 RNAi 작용제 | |
| EP4455285A3 (en) | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | |
| EP2355832B1 (en) | Compositions and methods for treating retrovirus infections | |
| US8691781B2 (en) | Compositions for treating respiratory viral infections and their use | |
| JP2016522674A5 (https=) | ||
| JP2016502858A5 (https=) | ||
| PE20220574A1 (es) | Oligonucleotidos gapmer modificados y metodos de uso | |
| JP2016521556A5 (https=) | ||
| KR20210130736A (ko) | B형 간염 바이러스 감염에 대한 RNAi 작용제 | |
| JP2017528441A5 (https=) | ||
| FI3800257T3 (fi) | Pan-genotyyppisiä aineita influenssavirusta vastaan ja menetelmiä niiden käyttämiseksi | |
| JP2019511471A5 (https=) | ||
| US20090117179A1 (en) | siDNA against Influenza Virus | |
| Zhang et al. | Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1 | |
| CN110214013A (zh) | 抗病毒剂及治疗病毒感染的方法 | |
| Nikitenko et al. | Targeting species D adenoviruses replication to counteract the epidemic keratoconjunctivitis | |
| AU2018330372B2 (en) | Single stranded oligonucleotides inhibiting endocytosis | |
| Heinrich et al. | A short hairpin loop-structured oligodeoxynucleotide targeting the virion-associated RNase H of HIV inhibits HIV production in cell culture and in huPBL-SCID mice | |
| US11046958B2 (en) | Antisense oligonucleotides that inhibit influenza virus replication and uses thereof | |
| CN111154755A (zh) | 一种双链寡核苷酸dna及其应用 | |
| US20240401050A1 (en) | Nucleic Acid Sponges | |
| JP4631084B2 (ja) | レトロウイルス組込み標的核酸 | |
| Seo et al. | Protection against lethal vaccinia virus infection in mice using an siRNA targeting the A5R gene | |
| JP5974221B2 (ja) | Ｈ７ｎ７亜型インフルエンザウイルスのヘマグルチニンに結合するアプタマー | |
| US20220090082A1 (en) | Gapmer antisense oligonucleotides targeting sars-cov-2 for treating covid 19 |